" class="no-js "lang="en-US"> Stéphane Degove - Medtech Alert
Thursday, October 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Stéphane Degove

Stéphane Degove

About Stéphane Degove

Stéphane has 17 years’ experience in Biotech/Pharma and Strategy. Graduated from ESCP (majoring in Finance), he worked at Sanofi in Finance and was co-founder and CFO of a biotechnology company in cancer and thrombosis, Endotis Pharma. Under his leadership, Endotis Pharma raised € 37 million from international funds and built a portfolio of innovative products developed up to Phase II.

Related Story

Industry News

 Exelixis Expands Portfolio with Acquisition of GamaMabs AMHR2 | Pharmtech Focus

Exelixis Acquires GamaMabs AMHR2

May 5 2021

Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an […]